Artificial Intelligence, AI In a whirlwind week for AI, OpenAI co-founder Ilya Sutskever ’s new venture secured $1 billion for ‘safe’ superintelligence, while AI-driven drug discovery hit roadblocks in clinical trials. Meanwhile, tech giants raced to perfect multilingual chatbots, researchers mined big data for insights, and a breakthrough in “personhood credentials” promised to distinguish humans from AI online. AI Whiz Raises $1B to Build ‘Safe’ Superintelligence OpenAI co-founder Ilya Sutskever’s new venture, Safe Superintelligence (SSI), has secured a cool $1 billion in funding, valuing the startup at a whopping $5 billion. With backing from tech heavyweights like Andreessen Horowitz and Sequoia , SSI is gearing up for a “straight shot to safe superintelligence,” prioritizing R&D over rapid commercialization. This move follows Sutskever’s dramatic OpenAI exit, where boardroom drama “diminished” […]
Original web page at www.pymnts.com
